ArticleApplied health economics and health policy2018

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.

Don Husereau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.